Abstract 231P
Background
Body mass index (BMI) has shown the associated with clinical outcomes of immune checkpoint inhibitors (ICIs) treatment in patients with several malignancies. We previously reported the association between clinical outcome in advanced urothelial carcinoma (UC) patients treated with pembrolizumab and BMI according to the WHO international classification. However, no patient in our cohort was grouped into obese (BMI 30kg/m2≤) and WHO BMI classification may be unsuitable for Asians. Therefore, we investigated the association between BMI classification developed for Asian people and clinical outcomes of pembrolizumab for advanced UC.
Methods
We retrospectively reviewed consecutive patients with advanced UC who received pembrolizumab between December 2003 and March 2023. Patients were divided into three groups based on BMI classification for Asians; the non-overweight group (BMI < 22.9 kg/m2), the overweight group (23 ≤ BMI < 24.9 kg/m2), and the obese group (BMI ≥ 25 kg/m2). Tumor response, progression-free survival (PFS), overall survival (OS), and incidence of adverse events (AEs) were compared among the groups. We additionally investigated factors associated with PFS using the multivariate analysis.
Results
Of 99 eligible patients, 54 (54.5%), 21 (21.2%) and 24 (24.2%) were in the non-overweight, overweight and obese group, respectively. PFS was significantly longer in the obese group (median 10.3 months) than that in the non-overweight (median 4.2 months) and the overweight group (median 2.3 months) (p=0.04). Multivariate analysis showed that obese was significantly associated with favorable PFS. The obese group had higher objective response rate and longer OS compared to other groups, although the difference did not reach the statistical significance. Multivariate analysis showed that obese was significantly associated with favorable PFS. There was no difference in the occurrence of irAEs among three groups.
Conclusions
BMI was associated with PFS for patients with advanced UC received pembrolizumab and BMI Asian classification may be more useful and suitable for Asian patients than that of WHO classification.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
373P - Investigating the impact of treatment on geriatric patients with locally advanced head and neck squamous cell carcinoma
Presenter: Yen Ting Liu
Session: Poster Display
Resources:
Abstract
374P - Immunohistochemical evaluation of oral lichen planus: A prospective clinical study
Presenter: Saravanan Sampoornam Pape
Session: Poster Display
Resources:
Abstract
375P - Survival and prognostic factors of head and neck squamous cell carcinoma patients treated with either definitive CCRT or post operative CCRT with platinum-based chemotherapy in Rajavithi hospital, Thailand
Presenter: wanit samadee
Session: Poster Display
Resources:
Abstract
376P - Nutrition as an independent prognostic factor in locally advanced nasopharyngeal carcinoma: A retrospective cohort study and propensity score-matched analysis
Presenter: haizhen yi
Session: Poster Display
Resources:
Abstract
377P - Oropharyngeal squamous cell carcinomas in Indian population: P16 positivity and treatment outcomes following chemoradiotherapy
Presenter: Parth Verma
Session: Poster Display
Resources:
Abstract
378P - A real-world retrospective analysis of the efficacy of pembrolizumab combined with chemotherapy as neoadjuvant treatment for locally advanced head and neck squamous cell carcinoma (LA HNSCC)
Presenter: zhu Liu
Session: Poster Display
Resources:
Abstract
379P - Nimotuzumab in combination with chemoradiation for patients with intermediate stage and locally advanced nasopharyngeal carcinoma: A retrospective comparative analysis using 5-year real-world survival data
Presenter: Andhika Rachman
Session: Poster Display
Resources:
Abstract
380P - An epidemiological analysis on the prevalence of oral cancer and its awareness among Irula tribes of South India
Presenter: Delfin Lovelina Francis
Session: Poster Display
Resources:
Abstract
381P - P16INK4 over-expression, early stages, keratinization, and surgical margin-free status are associated with better prognosis of oral squamous cell carcinoma (OSCC)
Presenter: Sumadi Lukman Anwar
Session: Poster Display
Resources:
Abstract
382P - Oral health disparities in privileged and underprivileged tribes of south India: A study of the prevalence of precancerous oral lesions
Presenter: Shanavas Palliyal
Session: Poster Display
Resources:
Abstract